

**Freedom of Information Request: 0366 2019/20**

- 1. In the past 12 months, how many patients with metastatic differentiated thyroid (refractory to radioactive iodine) cancer were treated with:**

QE:

**Axitinib 0**  
**Cabozantinib 0**  
**Lenvantinib 0**  
**Pazopanib 0**  
**Sorafenib 0**  
**Sunitinib 0**  
**Vandetanib 0**

HGS: Not applicable, we do not treat thyroid cancer

- 2. In the past 12 months, how many metastatic Renal Cell Carcinoma patients were treated with:**

UHB:

**Sunitinib 10**  
**Pazopanib 27**  
**Everolimus 0**  
**Temsirolimus 0**  
**Cabozantinib 6**  
**Nivolumab 9**  
**Axitinib 0**  
**Nivolumab + Ipilimumab 4**  
**Lenvantinib + Everolimus 0**  
**Tivozanib 0**  
**Pembrolizumab + Axitinib 0**  
**Avelumab + Axitinib 0**

- 3. In the past 12 months, how many metastatic Hepatic Cell Carcinoma patients were treated with:**

UHB:

**Bevacizumab 0**  
**Cisplatin 18**  
**Doxorubicin 0**  
**Everolimus 0**  
**Lapatinib 0**  
**Lenvantinib 6**  
**Regorafenib 1**  
**Sorafenib 9**  
**Sunitinib 0**